- info@pro1laser.com
- 1-604-649-1234
- Monday 07.00 am - 12.00 pm Sunday
Menu
Male pattern baldness, also known as androgenetic alopecia, is primarily due to a genetic predisposition of hair follicles to undergo miniaturization in response to androgen hormones. This condition, influenced by hormonal levels and genetic factors, leads to the progressive thinning and loss of hair in a significant number of individuals. In men, this form of alopecia typically results in a receding hairline and thinning at the temples, as well as baldness at the crown of the head, following a pattern that becomes more pronounced over time. Women experience androgenetic alopecia as widespread thinning of hair across the crown, which results in an increasingly visible scalp through a widening part. The hair may also become finer, taking on a frizzy appearance that exacerbates the look of thinning.
Understanding the progression and impact of androgenetic alopecia is crucial for timely intervention and management. Early signs in men can include a slight recession of the hairline, especially at the temples, often referred to as a “widow’s peak,” or thinning hair at the crown, which gradually evolves into more noticeable baldness. For women, the early stages may be less apparent, typically starting with gradual thinning where the hair parts, which may initially appear as simply having less volume or fuller hair.
This condition not only affects appearance but can also have profound psychological effects, contributing to stress, anxiety, and reduced self-esteem. The social and emotional toll underscores the importance of addressing androgenetic alopecia not just as a cosmetic issue but as a significant factor in overall well-being. Advancements in treatment have provided a range of options that can slow the progression of hair loss, stimulate regrowth, and help manage the condition’s psychological impacts. These include topical treatments like minoxidil, oral medications such as finasteride for men, and newer therapies like QR678® Neo, which targets hair follicle health directly.
Male pattern baldness is caused by elevated levels of dihydrotestosterone (DHT) hormone. Dihydrotestosterone is a metabolic product of the conversion of free testosterone by 5-alpha reductase. DHT causes the progressive shrinkage of hair follicles which may eventually lead to their becoming dormant.
Due to changes in hormonal levels as a person ages, onset of baldness with age may also take place. Aging causes a progressive decrease in the Anagen hair (growth phase of hair cycle) and leads to an increased number of dormant hair follicles.
Baldness is dependent on several genetic factors. It is strongly associated with the AR gene on the X chromosome. About 80% of the cases of Androgenetic Alopecia are due to genetic factors.
Premature baldness may be caused by an interplay of several factors such as nutritional deficiencies, glucose uptake, insulin resistance, androgen levels and other genetic factors. These must be carefully investigated while evaluating male pattern baldness.
he QR678® Neo therapy is a proprietary, first in class hair fall & hair regrowth therapy, which has revolutionized the treatment of hair fall in alopecia. This formulation was invented in India & has been named QR678 inspired by the new generation ubiquitous presence of “Quick Response“ QR code. 678 in Morse Code signifies “there is no answer”. This formulation has been named QR678® to signify a “Quick Response to a disease which earlier had no answer”.
Topical minoxidil and oral finasteride tablets.
The most important clinical trial evaluating the efficacy of minoxidil in androgenetic alopecia was performed in the USA – https://clinicaltrials.gov/ct2/show/NCT00151515
This clinical trial though was not neutral and was industry (Johnson & Johnson, manufacturer & patent holder for minoxidil) sponsored.
The primary purpose of the study was to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of male pattern hair loss. The secondary purpose was to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
In August 1988, the US FDA finally approved minoxidil for treating baldness in men under the trade name “Rogaine”. The agency concluded that although “the product will not work for everyone”, 39% of the men studied had “moderate to dense hair growth on the crown of the head”. This medicine was then recommended for female pattern hair loss, as well.
Minoxidil is generally well tolerated, but common side effects include burning or irritation of the eye, itching, redness or irritation at the treated area, and unwanted hair growth elsewhere on the body. Dandruff is a common problem as is Temporary hair loss. Manufacturers note that minoxidil-induced hair loss is a common side effect and describe the process as “shedding”.
We believe that minoxidil works well to stop or reduce hair fall in a majority of people, but does not work as well at hair regrowth.
Regular usage of minoxidil leads to compliance issues & most people do not use minoxidil in the recommended twice a day usage pattern, used in clinical trials.
As the QR678® Neo has no real side effects & causes hair growth, especially in minoxidil resistant cases, it is an interesting alternative to minoxidil & is preferred by a large number of patients.
Finasteride, a type 2-selective 5α-reductase inhibitor, was approved in 1997 as the first oral pharmacologic therapy for the treatment of men with androgenetic alopecia (Male pattern hair loss).
Three double-blind, randomized, placebo-controlled Phase III studies of finasteride were conducted in a sample of 1879 men aged between 18–41 years with mild to moderate AGA. Two of the studies enrolled men with predominantly vertex hair loss and one study enrolled men with predominantly frontal (anterior mid-scalp) hair loss. Finasteride 1 mg or matching placebo tablets were taken once daily for 24 months in the vertex studies and for 12 months in the frontal study. All three studies demonstrated that finasteride treatment led to a significant improvement in hair growth and slowing of further hair loss progression, while placebo-treated men showed significant hair loss.
The net improvement in hair count (finasteride vs. placebo) was 14% at 1 year and 16% at 2 years. Only 17% of men receiving finasteride lost hair based on hair count during the 2-year studies, compared with 72% of men receiving placebo. These data demonstrated that finasteride slowed the progression of hair loss.
The problem though was that drug-related adverse events reported by ≥1% of men receiving finasteride 1 mg in the first year were decreased libido (reported by 1.8% of men on finasteride vs. 1.3% on placebo), erectile dysfunction (reported by 1.3% of men on finasteride vs. 0.7% on placebo) and ejaculation disorder (1.2% of men on finasteride vs. 0.7% on placebo). Approximately 1% (1.2%) of men receiving finasteride discontinued treatment due to these adverse events (compared with 0.9% of men in the placebo group) with resolution occurring after discontinuation of drug. This medicine was then recommended for female pattern hair loss, as well.
Although finasteride works well to stop or reduce hair fall in a majority of people, it does not work as well at hair regrowth. Regular usage of finasteride leads to compliance issues & most people do not use finasteride continuously, because of the side effects it has on sexuality.
As the QR678® Neo has no real side effects & cause hair growth, especially in minoxidil & finasteride resistant cases, it is an interesting alternative to finasteride & is preferred by a large number of patients.
QR678® Neo consists of a proprietary blend of natural growth factors, identical to those found in a healthy scalp, ensuring its safety for universal application. This precise formulation contains targeted concentrations of specific factors known to promote hair growth. With QR678® Neo, patients experience no side effects. The treatment is administered on an outpatient basis, with visible results emerging as early as eight weeks after commencement. Hear directly from our patients about their experiences with the QR678® Neo hair loss treatment.
QR678® Neo treatments involve 5 to 10 sessions, spaced approximately 2-3 weeks apart. Visible improvements can be observed within a few weeks following the commencement of the therapy. Once optimal results are attained, further injections are unnecessary unless hair loss recurs. This enduring effect is due to QR678® Neo’s capacity to rejuvenate hair follicles. Discover the reasons behind QR678® Neo’s high efficacy in reducing hair loss and enhancing hair regrowth.
QR678® Neo offers a safe treatment experience without any side effects, enabling you to continue with your day-to-day activities right after each session. It is recommended to use a mild shampoo at least a day post-treatment and refrain from scratching or rubbing the area treated. If any concerns arise, consult your treatment provider for guidance.
Genetic hair loss, often hereditary and observed in both men and women, can indeed be managed effectively if treatment commences early. This type of hair loss, which frequently runs in families, typically follows a distinctive pattern: an M or W shape in men and thinning along the hair part in women. If you have a family history of patterned baldness, it’s crucial to monitor your hair health closely and consult a doctor at the first sign of hair loss.
There are several well-established treatments for genetic hair loss, including:
Alopecia following chemotherapy is a widespread and emotionally impactful side effect of cancer treatments. The fear of hair loss often deters patients from undergoing necessary therapies. While hair loss from chemotherapy is usually temporary, regrowth can take months or even up to a year. However, recent advancements in treatment can expedite recovery:
These treatments offer hope and options for those facing hair loss due to chemotherapy, providing a path to recovery and helping to mitigate one of the most challenging aspects of cancer treatment.
QR678® Neo is a first-of-its-kind product developed by a group of clinical scientists after extensive research.
